Alkermes (ALKS) Stock: Buy, Sell, or Hold?
$47.69
-0.20 (-0.42%)
▼
5d:
+7.07%
30d:
+22.03%
90d:
-2.79%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 03, 2026
0d
Protect ALKS Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (32%)
Quality Score
41/100
Position
EXTENDED
30-Day Fair Range
$41.17 – $46.12
Position: EXTENDED
Forward P/E & Valuation
35.4x
STRETCHED
vs 22.5x historical avg
Wall Street Target
$57.74
+20.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$44.07 / $48.26
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: ALKS shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When ALKS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.14
Based on -4.3% avg growth
INTRINSIC VALUE TODAY
$14.99
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALKS is currently trading at $47.69, which is considered extended relative to its 30-day fair value range of $41.17 to $46.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.4) compared to its historical average (22.5). At these levels, the market is pricing in 16.3% annual earnings growth.
Technical Outlook: Technically, ALKS is in a strong downtrend. The price is approaching resistance at $48.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ALKS scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $57.74 (+20.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALKS is in a strong downtrend. The price is approaching resistance at $48.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ALKS scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $57.74 (+20.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$41.17 -
$46.12
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.9%
Trading Range & Key Levels
30-Day Trading Range
$41.17 -
$46.12
Current vs Trading Range
EXTENDED
Support Level
$44.07
Resistance Level
$48.26
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding ALKS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.6% below Wall St target ($57.74)
- BULLISH: Expecting earnings turnaround to 16.3% growth with 21.8% revenue growth
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
35.40
Wall Street Target
$57.74
(+20.6%)
Revenue Growth (YoY)
21.8%
Earnings Growth (YoY)
-81.6%
Valuation Premium vs History
+16.3% premium
PE vs Historical
35.4 vs 22.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+16.3%
(market-implied from PE analysis)
1-Year Target
$55.70
(+16%)
2-Year Target
$64.77
(+35%)
3-Year Target
$75.33
(+57%)
3-Yr Target (if PE normalizes)
(PE: 35→23)
PE COMPRESSION
$47.89
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.4, Growth: -12.7%)
$34.91
(+-27%)
Base:
(SPY PE: 19.9, Growth: -12.7%)
$19.59
(-59%)
Bear:
(PE: 16.9, Growth: -12.7%)
$16.65
(-65%)
Share ALKS Analysis
Share this live ALKS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ALKS)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jul 16, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish sentiment prevails on StockTwits regarding $ALKS with no new information available from Yahoo Finance news.
Key Retail Themes:
Bullish sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:13 PM ET
Data refreshes hourly during market hours. Next update: 2:13 PM
Data refreshes hourly during market hours. Next update: 2:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALKS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 43 HOLD |
Advanced ALKS Option Strategies
Professional options setups generated by AI based on today's ALKS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ALKS Research Pages
